Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2015

01-12-2015 | Original Article

Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease

Authors: Noriko Kanauchi, Susumu Ookawara, Kiyonori Ito, Satsuki Mogi, Izumi Yoshida, Masafumi Kakei, San-e Ishikawa, Yoshiyuki Morishita, Kaoru Tabei

Published in: Clinical and Experimental Nephrology | Issue 6/2015

Login to get access

Abstract

Background

Type 2 diabetic kidney disease (DKD) is the most common cause of end-stage renal failure, and the prevention of its progression has been a topic of discussion.

Methods

Sixty type 2 DKD patients were retrospectively evaluated for 1 year. Factors independently affecting the annual Ccr decline were examined by multivariable linear regression analysis. Patients were further divided into 2 groups based on their degree of renal function, and between-group differences at study initiation were evaluated.

Results

Ccr values were 21.0 ± 11.8 mL/min/1.73 m2 at study initiation, and 15.7 ± 10.9 mL/min/1.73 m2 after 1 year of observation. The multivariable linear regression analysis indicated salt intake (standardized coefficient: −0.34, P = 0.010) and urinary protein excretion (standardized coefficient: −0.33, P = 0.011) to be factors independently affecting the annual Ccr decline. Although decliners (−9.8 ± 4.7 mL/min/1.73 m2/year) had a significantly higher salt intake than non-decliners (−1.1 ± 3.8 mL/min/1.73 m2/year) at study initiation, this difference disappeared at the end of the study as a result of intensive dietary education. In 21 decliners with an additional year of follow-up, the annual Ccr decline significantly improved from −10.1 ± 5.3 to −5.3 ± 7.4 mL/min/1.73 m2/year (P = 0.02).

Conclusion

Salt intake and urinary protein excretion were associated with annual Ccr decline in type 2 DKD patients. Furthermore, dietary education covering salt intake may have positively affected the change in Ccr.
Literature
1.
go back to reference Rotz E, Rychlik I, Locatelli F, Halimi S. End stage renal failure in type 2 diabetes: a medical catastrophe of world wide dimensions. Am J Kidney Dis. 1999;34:795–808.CrossRef Rotz E, Rychlik I, Locatelli F, Halimi S. End stage renal failure in type 2 diabetes: a medical catastrophe of world wide dimensions. Am J Kidney Dis. 1999;34:795–808.CrossRef
2.
go back to reference Byme C, Steenkamp R, Castledine C, Ansell D, Feehally J. UK renal registry 12th annual report: chapter 4: UK ESRD prevalent rates in 2008: national and centre-specific analysis. Nephron Clin Pract. 2010;115(Suppl 1):c41–67. Byme C, Steenkamp R, Castledine C, Ansell D, Feehally J. UK renal registry 12th annual report: chapter 4: UK ESRD prevalent rates in 2008: national and centre-specific analysis. Nephron Clin Pract. 2010;115(Suppl 1):c41–67.
3.
go back to reference Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan. Ther Apher Dial. 2012;16:483–521.CrossRefPubMed Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan. Ther Apher Dial. 2012;16:483–521.CrossRefPubMed
4.
go back to reference Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071–8.CrossRefPubMed Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071–8.CrossRefPubMed
6.
go back to reference Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.CrossRefPubMed Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.CrossRefPubMed
7.
go back to reference Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E. Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2012;16:878–83.PubMed Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E. Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2012;16:878–83.PubMed
8.
go back to reference Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, Bonora E. Predicted of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.CrossRefPubMed Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, Bonora E. Predicted of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.CrossRefPubMed
9.
go back to reference Altemtam N, Russell J, Nahas ME. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant. 2012;27:1847–54.CrossRefPubMed Altemtam N, Russell J, Nahas ME. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant. 2012;27:1847–54.CrossRefPubMed
10.
go back to reference Suckling RJ, He FJ, Macgregor GA. Alterd dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;8:CD006763. doi:10. 1002/14651858. CD006763.pub2. Suckling RJ, He FJ, Macgregor GA. Alterd dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;8:CD006763. doi:10. 1002/14651858. CD006763.pub2.
11.
go back to reference Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58–65.CrossRefPubMed Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58–65.CrossRefPubMed
12.
go back to reference Japan Nephrology Society. Special issue. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034–191.PubMed Japan Nephrology Society. Special issue. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034–191.PubMed
13.
go back to reference Maeda CY, Schaan BD, Oliveira E, Oliveira V, De Angelis KD, Irigoyen MC. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Clin Exp Pharmacol Physiol. 2007;34:574–80.CrossRefPubMed Maeda CY, Schaan BD, Oliveira E, Oliveira V, De Angelis KD, Irigoyen MC. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Clin Exp Pharmacol Physiol. 2007;34:574–80.CrossRefPubMed
14.
go back to reference Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, Mcgrill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int. 2003;63:1499–507.CrossRefPubMed Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, Mcgrill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int. 2003;63:1499–507.CrossRefPubMed
15.
go back to reference Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.CrossRefPubMed Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.CrossRefPubMed
16.
go back to reference Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 1990;38:384–94.CrossRefPubMed Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 1990;38:384–94.CrossRefPubMed
17.
go back to reference Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;2007(25):1105–87.CrossRef Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;2007(25):1105–87.CrossRef
18.
go back to reference Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–53.CrossRefPubMed Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–53.CrossRefPubMed
20.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
21.
go back to reference Diamandopoulos A, Goudas P, Arvanitis A. Comparison of estimated creatinine clearance among five formulae (Cockroft–Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24 h-urine-collection creatinine clearance. Hippokratia. 2010;14:98–104.PubMedCentralPubMed Diamandopoulos A, Goudas P, Arvanitis A. Comparison of estimated creatinine clearance among five formulae (Cockroft–Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24 h-urine-collection creatinine clearance. Hippokratia. 2010;14:98–104.PubMedCentralPubMed
22.
go back to reference Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on aging: impact on renal drug dosing. Pharmacotherapy. 2013;33:912–21.PubMedCentralCrossRefPubMed Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on aging: impact on renal drug dosing. Pharmacotherapy. 2013;33:912–21.PubMedCentralCrossRefPubMed
23.
go back to reference Dowling TC, Matzke GR, Murphy JE, Burckart GL. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacology. 2010;30:776–86. Dowling TC, Matzke GR, Murphy JE, Burckart GL. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacology. 2010;30:776–86.
24.
go back to reference Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal disease: a meta-analysis. Ann Intern Med. 1996;124:627–32.CrossRefPubMed Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal disease: a meta-analysis. Ann Intern Med. 1996;124:627–32.CrossRefPubMed
25.
go back to reference Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, Shikata K, Murakami Y, Tomino Y, Yamada K, Araki SI, Kashiwagi A, Kikkawa R. Low-protein diet study group. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomized controlled trial. Diabetologia. 2009;52:2037–45.PubMedCentralCrossRefPubMed Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, Shikata K, Murakami Y, Tomino Y, Yamada K, Araki SI, Kashiwagi A, Kikkawa R. Low-protein diet study group. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomized controlled trial. Diabetologia. 2009;52:2037–45.PubMedCentralCrossRefPubMed
26.
go back to reference Williams ME, Stanton R. Chapter 31-nutritional and metabolic management of the diabetic patients with chronic kidney disease and chronic renal failure. In: Kopple JD, Massry SG, Kalantar-Zadeh K, editors. Nutritional management of renal disease. 1st ed. Amsterdam: Elsevier; 2013. p. 485–502.CrossRef Williams ME, Stanton R. Chapter 31-nutritional and metabolic management of the diabetic patients with chronic kidney disease and chronic renal failure. In: Kopple JD, Massry SG, Kalantar-Zadeh K, editors. Nutritional management of renal disease. 1st ed. Amsterdam: Elsevier; 2013. p. 485–502.CrossRef
Metadata
Title
Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease
Authors
Noriko Kanauchi
Susumu Ookawara
Kiyonori Ito
Satsuki Mogi
Izumi Yoshida
Masafumi Kakei
San-e Ishikawa
Yoshiyuki Morishita
Kaoru Tabei
Publication date
01-12-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1118-y

Other articles of this Issue 6/2015

Clinical and Experimental Nephrology 6/2015 Go to the issue

Acknowledgment

List of referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine